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Background: Age at symptom onset (ASO) is a prognostic factor that could affect
the accrual of disability in multiple sclerosis (MS) patients. Some factors are known
to influence the risk of multiple sclerosis (MS), but their influence on the ASO is less
well-investigated.
Objective: Examine the associations between known or emerging MS risk factors and
ASO.
Methods: This was a multicenter study, incident cases (n = 279) with first clinical
diagnosis of demyelinating event aged 18–59 years recruited at four Australian
centres (latitudes 27◦-43◦S), from 1 November 2003 to 31 December 2006.
Environmental/behavioral variables and initial symptoms were recorded at baseline
interview. Linear regression was used to assess the association between risk factors
and ASO.
Results: Five factors were significantly associated with ASO: a history of tobacco
smoking was associated with 3.05-years later ASO (p = 0.002); a history of marijuana
use was associated with 6.03-years earlier ASO (p < 0.001); progressive-onset cases
had 5.61-years later ASO (p = 0.001); an initial presentation of bowel & bladder and
cerebral dysfunctional were associated with 3.39 (p= 0.017) and 4.37-years (p= 0.006)
later ASO, respectively. Other factors, including sex, offspring number, latitude of study
site, history of infectious mononucleosis, HLA-DR15 & HLA-A2 genotype, 25(OH)D
levels, and ultraviolet radiation exposure were not associated with ASO. Including all
five significant variables into one model explained 12% of the total variance in ASO.
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Conclusion: We found a novel association between a history of tobacco smoking
and later onset, whereas marijuana use was associated with earlier onset. Behavioral
factors seem important drivers of MS onset timing althoughmuch of the variance remains
unexplained.
Keywords: first demyelinating event, age at symptom onset, smoking, offspring number, marijuana, multiple
sclerosis
INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory and
degenerative disease of the central nervous system (CNS), caused
by a complex interplay between genetic and environmental
factors (1). HLA-DR15∗01 genotype (2), lower vitamin D (3) or
exposure to ultraviolet radiation (UVR) (4), tobacco use (5), and
past infection with Epstein-Barr virus (6) are the main factors
implicated in MS risk. Our group recently demonstrated that
these risk factors could explain 63.8% of the attributable risk
(7), with 53.3% of that due to the environmental factors. Other
factors such as HLA-A2 genotype (8) (protective), offspring
number (9) (protective), and marijuana use (5) (detrimental),
have some evidence of involvement in MS risk.
While a number of studies have examined risk factors for
the onset of MS, far fewer have tested associations with age at
symptom onset (ASO), which is the age at which first symptoms
suggestive of future MS occur. Current studies (10, 11) mostly
suggest a significant prognostic value of ASO in patients withMS,
with an early onset correlated with a benign disease progression.
Some studies showed that lower sun exposure in adolescence
was associated with earlier ASO (12, 13). One cohort study
(n = 895 cases) found no difference in ASO between never
and ever smokers (32.29 and 32.75 years, respectively) (14). One
study (n = 816) found that cases with HLA-DR15 risk genotype
had roughly 2.5-years earlier onset (15), but a later meta-
analysis (n = 2,201) showed no association (16). The association
betweenHLA-A2 genotype andASO has also yielded inconsistent
findings (17, 18). Our group (19) found that progressive-onset
patients had ∼9 years later ASO than relapsing-onset patients
(p < 0.001).
In view of the conflicting evidence presented above, this paper
examines the associations between risk factors for MS onset and
ASO in a cohort recruited soon after the first clinical diagnosis of
CNS demyelination (FCD).
METHODS
The Ausimmune Study was an Australian multicenter case-
control study (20). Case participants were aged 18–59 years and
resident in a study region: Brisbane city (latitude 27◦ South),
Newcastle city and surrounds (33◦S), Geelong city and the
Western Districts of Victoria (37◦ S), or the state of Tasmania
(∼41–43◦S). Incident cases (n = 282) were referred to the study
by medical specialists, following a FCD. A study neurologist
confirmed the date and symptomatology of the demyelinating
event(s) that led to study participation and conducted a full
neurologic examination. In subsequent follow-up (AusLong
study) (21), 3 cases were confirmed as non-MS, and 19 cases were
confirmed as primary-progressive MS (PPMS). Among all 279
cases, 217 had been diagnosed as MS at 5-year review. Among
260 relapsing-onset cases, 219 had their first demyelinating event
(FDE) during the study recruitment period (1 Nov 2003 to 31
Dec 2006), with remaining cases having had a prior, previously
unrecognized neurological event.
The Ausimmune Study was approved by nine regional Human
Research Ethics Committees. All participants gave written
informed consent.
Measurements
Demographic, environmental, behavioral and neurological data
were collected by self-reported questionnaire and face-to-face
interview. Serum samples and biometric measures were taken at
face-to-face interview.
Using the Expanded Disability Status Scale (EDSS), clinical
presentation was rated for seven function groups (pyramid,
cerebellar, brainstem, sensory, bowel & bladder, cerebral,
and visual) using 6–8 point scales. It was assessed by a
neurologist via face-to-face interview at baseline. Questionnaire
data collected included: a detailed smoking history of tobacco
and marijuana use (ever smoked, current smoking status, age
started/stopped smoking, pack-years of cigarette smoking, pack-
years of marijuana use); history of infectious mononucleosis
(“have you ever had glandular fever”); number and age of all live
births; and for females only, the age at menarche. Participants
completed a personal residence calendar (to assist recall of past
events), completing for each year of life from age 6 years the
location of residence and leisure time in the sun in summer
and winter. With the latitude and longitude of the location,
average daily ambient erythemally weighted UVR was calculated
for every year of life for each participant (4). For each participant,
UVR dose (kJ/m2) was estimated for the relevant periods of life
by multiplication of the average hours per day outside in each
season by the average UVR for that season, and summed over the
relevant years. Annual UVR exposure was assigned by adding the
summer and winter UVR dose.
Serum concentrations of 25(OH)D were measured using
liquid chromatography tandem mass spectrometry. Skin
reflectance on the buttock was measured using a hand-
held spectrophotometer (Minolta CM-2500D) to estimate
cutaneous melanin density (4). The genotyping of HLA-DR15
(SNP rs9271366) was performed by the SNPline method
(KBiosciences, Hoddesdon Herts, UK). The genotyping of
HLA-A2 (SNP rs2844821 on Illumina Custom MS Chip) was
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performed by the Hussman Institute for Human Genomics,
University of Miami.
Data Management and Analysis
ASO was calculated by subtracting the date of birth from the date
of first symptom onset (as determined by review of data by the
study neurologist team). Where only the year of symptom onset
was recorded, the onset date was assigned as 15th of June of that
year and if only the month was known it was assigned as the
15th of the month [year of FDE was recorded in 27 cases, but
the results were robust when these data were omitted from the
analysis (data not shown)].
Because 25(OH)D levels vary substantially by season, we
deseasonalised 25(OH)D levels in each study center using a
sine-cosine function, as described previously (4). The 25(OH)D
level was modeled as both a continuous and categorical variable
(using commonly used cut-points, <50, 50–75, >75–100, >100
nmol/L).
Due to the non-significant association between the degree
of clinical presentation and ASO in patients with each clinical
symptom (p > 0.05), clinical presentation of the seven function
groups were coded as no or yes in our analysis.
Log-binomial regression was used to assess the association
between categorical variables. Linear regression was used to
assess the association between potential predictors and ASO. We
mostly examined risk factors that occurred prior to the initial
symptom onset to ensure proper temporality, except 25(OH)D
was measured at the baseline review. For variables that were
inherently associated with age (e.g., smoking, UVR exposure,
offspring number), we summarized the information prior to a
specific age (e.g., 28 years for smoking, 31 years for marijuana
and offspring number) and examined the associations with ASO
after this age to obtain a less biased estimate. The distribution
of ASO was left skewed, and a Box-Cox power transformation
was applied to reduce heteroskedasticity and thus satisfy the
requirements of linear regression. All coefficients presented in the
results were back-transformed to the original scale.
In preliminary analyses, participants in Tasmania had a later
ASO than other study centers (mean difference: 3.19, 95% CI
0.73–5.65, p = 0.011). The higher ASO was likely driven by
the higher average age of the Tasmanian population, but the
collinearity between the population mean age and study center
(r= 0.91, p< 0.001) made adjustment not possible. We therefore
divided cases into five-year ASO groups (15–19 years, 20–24
years, 25–29 years, 30–34 years, 35–39 years, 40–44 years, 45–
49 years, 50–54 years, 55–59 years) in each study center, and
standardized the ASO to the age distribution in the whole
Australian population. After standardization, ASO (from highest
to lowest latitude: 37.2, 37.6, 37.0 & 37.2 years, respectively) was
similar in the four different study centers.
In the basic multivariable model, we adjusted for sex, study
center, and MS onset type (relapsing vs. progressive onset). For
UVR exposure analysis, we did not adjust for study center due
to collinearity (latitude and ambient UVR are strongly negatively
correlated). We adjusted for buttock melanin density to take
natural skin type into consideration. For smoking analyses, we
further adjusted for tobacco or marijuana smoking, due to the
significant positive correlation (r = 0.40, p < 0.001).
After the univariable and multivariable analyses of each
category of exposures, we built a mutually adjusted model
including all significant exposures, and examined the total
variance explained by these exposures. The relative contribution
of each variable was calculated as the change of the residual sum
of squares when comparing the model without the variable with
the full model.
We conducted a sensitivity analysis restricted to cases with
FDE during the recruitment period and excluding those whose
ASO was less certain. We performed another separate analysis
restricted to cases who had converted to MS by a 5-year follow-
up, (21) thus excluding cases who may never convert to MS.
We were concerned that some associations were the result of
an age or cohort effect. To examine this we used the controls
(n = 545) and assigned the same ASO of the cases to their age
and sex-matched controls. With the Australian Electoral Roll,
we randomly selected controls and matched to cases on age
(within two years), sex, and study region (60% participated of
those originally contacted). The final case:control matching ratio
averaged 1:2 (20). If an association was also observed in controls,
then that is likely due to an age or cohort effect.
All statistical analyses were undertaken using Stata/SE 12.1
(College Park, TX).
RESULTS
The mean ASO for the total cohort was 37.3 years and 76.7%
were females. ASO for those who had converted to MS at 5-year
follow-up (n= 217) was 37.0 years and for cases with FDE during
the recruitment period (n = 219) was 36.9 years. All primary
analyses were based on all patients with FDE (n = 279), and
sensitivity analyses including patients had converted to MS at 5-
year review (n = 217) or patients with FDE during recruitment
period (n= 219) were presented in the last section of result.
Sex, HLA-DR15, HLA-A2 and History of
Infectious Mononucleosis
We found no significant associations between ASO and sex,
history of IM, HLA-DR15 genotype, or HLA-A2 genotype
(Table 1; Supplementary Table 1).
25(OH)D and UVR Dose
No seasonal pattern was seen in the association between season
of FDE and ASO (F = 0.61, p = 0.72). There was no association
between deseasonalised 25(OH)D level and ASO (Table 1). Time
between FDE and 25(OH)D being taken did not modify the
association between 25(OH)D and ASO (pinteractio n = 0.38).
Cumulative UVR dose (summer, winter, and combined) within
different risk windows (e.g., 5, 10, and 15 years) prior to onset and
UVR dose during adolescence (6-15 years) showed no convincing
associations with ASO (Table 1; Supplementary Table 2).
Onset Type and Initial Symptoms
ASO of progressive-onset patients was 5.61-years later than
relapsing-onset patients (p = 0.013) (Table 2). There was
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TABLE 1 | Associations between sex, IM history, HLA-DR15 genotype, HLA-A2 genotype, 25(OH)D, UVR exposure and age of symptom onset.
Univariable Multivariable
No. (%) β (95% CI) p β (95% CI) p
SEXa
Male 65 (23.30) 37.50 (35.17, 39.83) c 37.21 (34.90, 39.52)c
Female 214 (76.70) −0.28 (−2.94, 2.38) 0.84 +0.15 (-2.49, 2.80) 0.91
PAST HISTORY OF IMa
No 200 (72.99) 37.61 (36.30, 38.92)c 37.7 (36.41, 39.00)c
Yes 74 (27.01) −1.18 (−3.70, 1.34) 0.36 −1.33 (−3.83, 1.18) 0.30
PAST HISTORY OF IM (EXCLUDING THOSE WHO DID NOT KNOW WHETHER THEY HAD A HISTORY OF IM)a
No 181 (70.98) 37.23 (35.85, 38.61)c 37.32 (35.96, 38.67)c
Yes 74 (29.02) −0.85 (−3.41, 1.71) 0.51 −0.96 (−3.49, 1.58) 0.46
HLA-DR15 (RS9271366)a
AA 106 (43.80) 37.19 (35.38, 39.00)c 36.89 (34.91, 38.86)c
AG 123 (50.83) +0.40 (−2.07, 2.86) 0.75 +1.42 (−1.26, 4.09) 0.30
GG 13 (5.37) +3.18 (−2.26, 8.63) 0.25 +4.74 (−2.43, 11.91) 0.20
Trend 0.38 0.15
HLA–A2 (RS2844821)a
AA 117 (54.42) 36.93 (35.22, 38.64)c 37.17 (35.43, 38.92)c
AG 98 (45.58) +1.79 (−0.74, 4.31) 0.17 +1.38 (−1.24, 4.01) 0.30
SEASON OF FDEb
Spring 70 (25.09) 36.9 (34.47, 39.34)c 37.2 (34.69, 39.7)c
Summer 72 (25.81) +1.00 (−2.27, 4.26) 0.55 0.01 (−3.39, 3.42) 0.99
Autumn 61 (21.86) +0.05 (−3.28, 3.37) 0.98 −0.42 (−3.8, 2.97) 0.81
Winter 76 (27.24) +0.40 (−2.87, 3.66) 0.81 0.43 (−2.89, 3.76) 0.80
Deseasonalised 25(OH)D, continuous (per 10 nmol/L increase)b −0.04 (−0.48, 0.40) 0.87 −0.03 (−0.48, 0.41) 0.88
DESEASONALISED 25(OH)Db
<50 nmol/L 33 (15.57) 36.95 (33.68, 40.22)c 36.92 (33.64, 40.19)c
50–75 nmol/L 70 (33.02) −0.19 (−4.16, 3.77) 0.92 −0.33 (−4.32, 3.65) 0.87
76 – 100 nmol/L 70 (33.02) −0.68 (−4.65, 3.28) 0.74 −0.75 (−4.72, 3.22) 0.71
> 100 nmol/L 39 (18.40) +1.26 (−3.18, 5.71) 0.58 +1.19 (−3.25, 5.64) 0.60
Trend 0.67 0.67
WINTER UVR DOSE IN THE 15 YEARS BEFORE ONSETb
0–0.93 x102 kJ/m2 64 (24.81) 39.62 (37.43, 41.81)c 39.68 (37.47, 41.9)c
> 0.93–1.59 × 102 kJ/m2 65 (25.19) −3.05 (−6.12, 0.02) 0.05 –3.37 (–6.46, –0.28) 0.032
> 1.59–2.51 × 102 kJ/m2 64 (24.81) −1.95 (−5.04, 1.14) 0.22 −2.06 (−5.22, 1.09) 0.20
> 2.51–8.47 × 102 kJ/m2 65 (25.19) −1.43 (−4.51, 1.65) 0.36 −1.37 (−4.50, 1.76) 0.39
Trend 0.53 0.57
SUMMER UVR DOSE IN THE 15 YEARS BEFORE ONSETb
0–5.53 x102 kJ/m2 64 (24.71) 39.82 (37.66, 41.97)c 39.54 (37.35, 41.73)c
> 5.53–7.37 × 102 kJ/m2 65 (25.10) –3.91 (–6.91, –0.91) 0.011 –3.75 (–6.77, –0.73) 0.015
> 7.37–9.99 × 102 kJ/m2 65 (25.10) –3.95 (−6.95, –0.95) 0.010 –3.87 (–6.93, –0.81) 0.013
> 9.99–18.99 × 102 kJ/m2 65 (25.10) +0.38 (−2.66, 3.42) 0.81 +1.07 (−2.15, 4.28) 0.52
Trend 0.81 0.65
ANNUAL UVR DOSE IN THE 15 YEARS BEFORE ONSETb
0–6.87 × 102 kJ/m2 64 (24.81) 39.35 (37.18, 41.52)c 39.09 (36.89, 41.3)c
> 6.87–9.30 × 102 kJ/m2 65 (25.19) –3.13 (–6.15, –0.10) 0.043 −3.01 (−6.07, 0.04) 0.053
> 9.30–12.00 × 102 kJ/m2 64 (24.81) –3.42 (–6.45, –0.38) 0.027 –3.26 (–6.37, –0.15) 0.040
> 12.00–22.46 × 102 kJ/m2 65 (25.19) +0.85 (−2.21, 3.91) 0.59 +1.41 (−1.79, 4.61) 0.39
Trend 0.64 0.48
Statistical significance (p < 0.05) is denoted in bold and italics.
aadjusted for sex, MS onset type and study center; badjusted for sex, MS onset type and buttock melanin density; cmean ASO of the reference group.
MS, multiple sclerosis; IM, infectious mononucleosis; UVR, ultraviolet radiation; FDE, first demyelinating event.
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TABLE 2 | Associations between onset type and initial symptomatology and age of symptom onset.
Univariable analysis Multivariable analysisa
No. (%) β (95% CI) p β (95% CI) p
MS ONSET TYPE
Relapsing-onset 258 (92.47) 36.99 (35.84, 38.15)b 36.95 (35.8, 38.09)b
Progressive-onset 21 (7.53) +4.86 (0.44, 9.28) 0.031 +5.61 (1.17, 10.05) 0.013
ONSET SYMPTOMS
Pyramidal dysfunction -no 150 (58.37) 37.51 (35.98, 39.04)b 37.86 (36.33, 39.38)b
Pyramidal dysfunction -yes 107 (41.63) +0.21 (−2.17, 2.58) 0.86 −0.52 (−2.94, 1.90) 0.67
Cerebellar dysfunction -no 185 (72.27) 36.89 (35.53, 38.26)b 37.01 (35.66, 38.37)b
Cerebellar dysfunction -yes 71 (27.73) +2.83 (0.24, 5.41) 0.032 +2.52 (−0.08, 5.12) 0.06
Brainstem dysfunction -no 192 (75.59) 37.43 (36.06, 38.79)b 37.4 (36.06, 38.75)b
Brainstem dysfunction -yes 62 (24.41) −0.13 (−2.90, 2.64) 0.93 0.15 (−2.59, 2.89) 0.92
Sensory dysfunction -no 114 (45.6) 37.6 (35.83, 39.37)b 37.56 (35.81, 39.3)b
Sensory dysfunction -yes 136 (54.4) −0.48 (−2.88, 1.92) 0.70 −0.33 (−2.70, 2.05) 0.79
Bowel & Bladder dysfunction -no 210 (79.55) 36.84 (35.56, 38.12)b 36.85 (35.58, 38.12)b
Bowel & Bladder dysfunction -yes 54 (20.45) +3.39 (0.57, 6.20) 0.019 +3.49 (0.63, 6.34) 0.017
Cerebral dysfunction -no 218 (83.52) 36.71 (35.47, 37.95)b 36.87 (35.64, 38.1)b
Cerebral dysfunction-yes 43 (16.48) +5.12 (2.08, 8.15) 0.001 +4.37 (1.28, 7.46) 0.006
Visual dysfunction -no 178 (70.92) 37.64 (36.25, 39.03)b 37.74 (36.38, 39.10)b
Visual dysfunction -yes 73 (29.08) −0.80 (−3.38, 1.77) 0.54 −1.00 (−3.54, 1.54) 0.44
ONSET SYMPTOMS IN RELAPSING-ONSET CASES
Pyramidal dysfunction -no 147 (61.51) 37.22 (35.70, 38.75)b 37.35 (35.84, 38.86)b
Pyramidal dysfunction -yes 92 (38.49) −0.09 (−2.55, 2.37) 0.94 −0.36 (−2.80, 2.09) 0.77
Cerebellar dysfunction -no 179 (74.27) 36.55 (35.18, 37.92)b 36.55 (35.19, 37.91)b
Cerebellar dysfunction -yes 62 (25.73) +2.82 (0.11, 5.52) 0.041 +2.91 (0.21, 5.60) 0.034
Brainstem dysfunction -no 179 (74.9) 36.79 (35.39, 38.18)b 36.78 (35.41, 38.16)b
Brainstem dysfunction -yes 60 (25.1) +1.06 (−1.72, 3.83) 0.46 +1.14 (−1.61, 3.90) 0.42
Sensory dysfunction -no 106 (45.3) 37.15 (35.34, 38.96)b 37.12 (35.33, 38.91)b
Sensory dysfunction -yes 128 (54.7) −0.29 (−2.73, 2.15) 0.81 −0.21 (−2.63, 2.21) 0.87
Bowel & Bladder dysfunction -no 201 (81.71) 36.52 (35.23, 37.81)b 36.43 (35.16, 37.71)b
Bowel & Bladder dysfunction -yes 45 (18.29) +3.33 (0.31, 6.34) 0.031 +3.90 (0.88, 6.93) 0.011
Cerebral dysfunction -no 205 (84.36) 36.35 (35.10, 37.61)b 36.47 (35.21, 37.72)b
Cerebral dysfunction -yes 38 (15.64) +5.20 (2.02, 8.39) 0.001 +4.54 (1.30, 7.78) 0.006
Visual dysfunction -no 166 (70.34) 37.10 (35.68, 38.51)b 37.23 (35.83, 38.63)b
Visual dysfunction -yes 70 (29.66) −0.24 (−2.84, 2.37) 0.86 −0.63 (−3.22, 1.96) 0.63
Statistical significance (p < 0.05) is denoted in bold and italics. aadjusted for sex, MS type, and study center; bmean ASO of the reference group.
no association between pyramidal, brainstem, sensory, visual
dysfunction and ASO. Cases with bowel/bladder and cerebral
symptoms had 3.49-years (p= 0.017) and 4.37-years (p= 0.006)
later onset, respectively, persisting on restriction to relapsing-
onset cases. Patients with cerebellar function impairment had
a 2.52-years later onset than those without cerebellar function
impairment (p = 0.057), and this association became significant
when restricting to relapsing-onset cases.
Smoking of Tobacco and Marijuana
Ever smokers had ∼5.11-years later onset than never smokers
(p < 0.001) (Table 3). The magnitudes were similar between past
smokers and current smokers. Cases with an earlier ASO might
have had less opportunity to start smoking, so we tested this by
only including cases with ASO ≥ 28 years (as 27 was the oldest
age of taking up smoking). While attenuating the magnitude, a
history of smoking remained significantly associated with ASO
(Table 3). We repeated the analysis in the matched controls, and
no difference of ASOwas shown (never smokers vs. ever smokers:
adjusted β = +0.11 years, 95% CI −1.54–1.77, p = 0.89),
suggesting the significant association in cases was not due to
an age or cohort effect. Among ever smokers, the ASO was
similar whether the smoking was taken up early (<16 years) or
later (pinteractio n = 0.26), or the duration was longer or shorter
(pinteractio n = 0.94). Among cases with ASO ≥ 28 years, total
pack years of tobacco use before age 27 was not associated with
ASO.
Marijuana use was more common in male cases than in
females (OR = 0.50, p = 0.020), and a history of marijuana use
was positively associated with smoking (OR= 8.05, p< 0.001). A
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TABLE 3 | Associations between smoking behaviors and age of symptom onset.
Univariable Multivariablea
No. (%) β (95% CI) P β (95% CI) P
SMOKING EVER
No 103 (37.59) 35.6 (33.79, 37.41)b 34.24 (32.41, 36.06)b
Yes 171 (62.41) +2.71 (0.42, 5.00) 0.021 +5.11 (2.74, 7.48) <0.001
SMOKING EVER (ASO ≥ 28 YEARS)
No 79 (35.59) 38.71 (37.2, 40.22)b 37.89 (36.45, 39.34)b
Yes 143 (64.41) +1.79 (−0.12, 3.71) 0.07 +3.05 (1.16, 4.95) 0.002
SMOKING STATUS
Never smoked 103 (37.59) 35.6 (33.78, 37.41)b 34.21 (32.38, 36.03)b
Past smokers 101 (36.86) +2.62 (0.04, 5.20) 0.047 +4.80 (2.21, 7.38) <0.001
Current smokers 70 (25.55) +2.85 (−0.01, 5.70) 0.05 +5.66 (2.69, 8.64) <0.001
Trend 0.037 <0.001
SMOKING STATUS (ASO ≥ 28 YEARS)
Never smoked 79 (35.59) 38.71 (37.2, 40.22)b 37.89 (36.44, 39.34)b
Past smokers 83 (37.39) +2.12 (−0.05, 4.30) 0.06 +3.05 (0.95, 5.14) 0.004
Current smokers 60 (27.03) +1.34 (−1.01, 3.68) 0.27 +3.06 (0.65, 5.47) 0.013
Trend 0.22 0.010
AGE UPTAKE SMOKING (ASO ≥ 28 YEARS)
≥16 years 84 (58.74) 41.45 (39.85, 43.05)b 41.21 (39.72, 42.7)b
<16 years 59 (41.26) −1.77 (−4.22, 0.68) 0.16 −1.35 (−3.66, 0.97) 0.26
DURATION OF SMOKING BEFORE AGE 27 (ASO ≥ 28 YEARS)
≤10 years 55 (40.44) 40.97 (38.99, 42.95)b 40.58 (38.67, 42.5)b
>10 years 81 (59.56) −0.51 (−3.07, 2.04) 0.69 +0.10 (−2.40, 2.60) 0.94
TOTAL PACK YEARS OF SMOKING BEFORE AGE 27 (ASO ≥ 28 YEARS)
0 93 (41.33) 39.19 (37.77, 40.61) 39.10 (37.71, 40.49)
1–2000 58 (25.78) +0.50 (−1.81, 2.81) 0.67 +0.61 (−1.67, 2.89) 0.60
>2000–20000 74 (32.89) +2.05 (−0.15, 4.25) 0.07 +2.24 (0.07, 4.41) 0.043
Trend 0.07 0.048
MARIJUANA EVER
No 190 (69.6) 38.58 (37.26, 39.9)b 39.23 (37.91, 40.55)b
Yes 83 (30.4) –4.04 (–6.43, –1.64) 0.001 −6.03 (−8.62, −3.45) <0.001
MARIJUANA EVER (ASO ≥ 31 YEARS)
No 151 (74.02) 41.29 (40.24, 42.34)b 41.5 (40.43, 42.57)b
Yes 53 (25.98) –2.20 (–4.14, –0.27) 0.026 –2.80 (–4.89, –0.71) 0.009
MARIJUANA STATUS
Never 190 (69.6) 38.58 (37.26, 39.90)b 38.56 (37.25, 39.87)b
Past users 63 (23.08) –4.08 (–6.73, –1.43) 0.003 –3.98 (–6.63, –1.34) 0.003
Current users 20 (7.33) −3.92 (−8.20, 0.37) 0.07 −3.46 (−7.87, 0.94) 0.12
Trend 0.003 0.004
MARIJUANA STATUS (ASO ≥ 31 YEARS)
Never 151 (74.02) 41.28 (40.24, 42.33)b 41.25 (40.22, 42.28)b
Past users 39 (19.12) −1.50 (−3.71, 0.70) 0.18 −1.35 (−3.58, 0.88) 0.24
Current users 14 (6.86) –4.06 (–7.16, –0.95) 0.010 –3.88 (–7.09, –0.66) 0.018
Trend 0.008 0.016
TOTAL PACK YEARS OF MARIJUANA USE BEFORE AGE 30 (ASO ≥ 31 YEARS)
0 180 (86.96) 40.96 (40.01, 41.92) 40.93 (39.99, 41.87)
1–30 13 (6.28) +1.13 (−2.70, 4.96) 0.56 +1.48 (−2.34, 5.30) 0.45
>30 14 (6.76) −3.16 (−6.34, 0.02) 0.052 −3.07 (−6.29, 0.14) 0.06
Trend 0.14 0.19
Statistical significance (p < 0.05) was denoted in bold and italics. aadjusted for sex, MS type, study centers and tobacco smoking status/marijuana use status; bmean ASO of the
reference group.
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history of marijuana use was associated with a 6.03-years earlier
ASO (Table 3). The magnitudes were similar between past users
and current users. We next evaluated associations among cases
with ASO ≥ 31 years (30 years was the oldest age of taking up
marijuana in this cohort). Magnitudes were attenuated but still
significant in this subgroup (Table 3). Among cases with ASO ≥
31 years, total pack years of marijuana use before age 30 was not
associated with ASO.
Offspring Numbers and Age at Menarche
Having children was strongly associated with a later ASO
(Table 4). The magnitude was potentially biased since those
with a later ASO may have had different opportunities to have
children.We therefore chose a cut-off point that balanced sample
size against the offspring number information, and by restricting
to those with ASO ≥ 31 years, we could include 204 cases
and 56.9% of participant offspring. A significant dose-dependent
association remained, albeit with reduced magnitude. This dose-
dependent association was found in both male and female
participants (pinteractio n = 0.11). When we repeated the analyses
in the controls, having more children was also significantly
associated with a later ASO (0 vs. 1: β = 4.55, p < 0.001; 0 vs.
≥2: β = 10.41, p < 0.001; ptrend < 0.001), and restricting to those
with ASO≥ 31 years still showed a significant association (0 vs. 1:
β = 1.39, p= 0.16; 0 vs.≥ 2: β = 3.48, p < 0.001; ptrend < 0.001).
This suggests that the significant association of offspring number
and ASO in cases was largely driven by an age or cohort effect.
The age of the participant when having their first child (≤20,
21–25, 26–30, 31–35, ≥36) was not associated with ASO; the
average ASO was around 41 years for each child birth age group.
There was no association between age of menarche and ASO
(p= 0.27).
Mutually Adjusted Model
We next built a combinedmodel based on the significant findings
(tobacco smoking, marijuana use, MS onset type, cerebral
dysfunction, and bowel & bladder dysfunction). The final model
explained ∼12% of the total variance in ASO, with marijuana
use and tobacco smoking having the largest relative contributions
(Table 5).
Sensitivity Analyses
Sensitivity analyses that restricted to cases with FDE during
the study recruitment period or diagnosed MS cases did not
materially alter the results (Supplementary Tables).
DISCUSSION
In this comprehensive study, we systematically evaluated the
association between ASO and risk factors for MS onset. A model
including all the significant factors explained 12% of the total
variance. Of the individual risk factors, a history of tobacco
smoking, progressive-onset type, and cerebral or bowel and
bladder symptoms at FDE were associated with a later onset,
while marijuana use was associated with an earlier onset.HLA-A2
genotype, HLA-DR15 genotype, latitude of study site, past UVR
dose, current 25(OH)D levels, history of IM, offspring number,
age of menarche, and sex were not associated with ASO.
A strength of our study is the detailed information on
exposure variables, as well as the study neurologist interview
and review of medical records for optimal assessment of the
ASO. Also, our findings showed a robustness when repeating
the analysis among those diagnosed with MS by 5-year review
(excluding some cases who may not convert to MS), as well
as restricting to cases with FDE during the study recruitment
TABLE 4 | Associations between offspring numbers/age at menarche and age of symptom onset.
Univariable Multivariable
No. (%) β (95% CI) p β (95% CI) p
OFFSPRING NUMBERa
0 111 (39.78) 31.16 (29.7, 32.63)c 31.37 (29.9, 32.83)c
1 39 (13.98) +5.97 (3.01, 8.92) <0.001 +5.51 (2.57, 8.44) <0.001
2 or more 129 (46.24) +11.12 (9.06, 13.18) <0.001 +10.88 (8.84, 12.93) <0.001
Trend <0.001 <0.001
OFFSPRING NUMBER (ASO ≥ 31 YEARS)b
0 89 (43.00) 39.25 (37.99, 40.5)c 39.22 (37.99, 40.45)c
1 37 (17.87) +1.67 (−0.74, 4.09) 0.18 +1.39 (−0.98, 3.77) 0.25
2 or more 81 (39.13) +3.42 (1.47, 5.36) 0.001 +3.61 (1.69, 5.54) <0.001
Trend 0.001 <0.001
AGE OF MENARCHEa
8–12 years 98 (46.23) 37.07 (35.17, 38.97)c 37.13 (35.24, 39.01)c
13–14 years 87 (41.04) +1.13 (−1.64, 3.9) 0.43 +0.98 (−1.8, 3.75) 0.49
15–23 years 27 (12.74) –4.19 (–8.24, –0.15) 0.042 −3.72 (−7.76, 0.32) 0.07
Trend 0.22 0.27
Statistical significance (p<0.05) is denoted in bold and italics. aModels adjusted for sex, MS type, and study centre; bsamples limited to those with ASO ≥ age 31 years and summarizing
offspring number < age 31 years, models adjusted for sex, MS type, and study centers. cmean ASO of the reference group.
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TABLE 5 | Mutually adjusted model including all factors associated with age of
symptom onset.
All cases (adjusted R2 = 0.12)
β (95% CI) P RC
Smoking status 5.0%
Never smoking 35.14 (33.31, 36.98)a
Past users +3.80 (1.21, 6.40) 0.004
Current users +4.72 (1.74, 7.71) 0.002
Trend 0.001
Marijuana history 9.2%
Never marijuana 39.47 (38.17, 40.78)a
Past users −5.49 (−8.29, −2.70) <0.001
Current users −7.23 (−11.75, −2.71) 0.002
Trend <0.001
MS onset type 0.6%
RRMS 37.58 (36.46, 38.69)a
PPMS +2.23 (−2.05, 6.52) 0.31
Cerebral function 5.9%
No 36.96 (35.78, 38.14)a
Yes +4.58 (1.68, 7.48) 0.002
Bowel & bladder function 1.2%
No 37.3 (36.09, 38.51)a
Yes +2.13 (−0.61, 4.87) 0.13
Statistical significance (p < 0.05) is denoted in bold and italics. RC, relative contribution.
amean ASO of the reference group.
period (excluding some whose ASO was slightly less certain). A
challenge was that some exposures were intrinsically associated
with ASO simply as a function of time. So we assessed the
temporal relationship through analyzing some exposure variables
before some age points and analyzing the association with ASO
after this point. This ensured that the participants included in the
analysis had an equal opportunity of exposure, but it substantially
reduced the power and assumed that there was nothing unusual
about those with a later vs. earlier onset. To examine whether
some observed associations were due to an age or cohort effect,
we tested whether an effect existed in the age and sex matched
controls. Based on that analysis, we believe that the association
between offspring number and ASO was not a true association.
In agreement with previous studies (19, 22, 23), progressive-
onset patients showed a later ASO than relapsing-onset patients.
In this study, patients with cerebral dysfunction (related to
cognition andmood) or bowel and bladder symptoms at FDE had
a 4.4 and 3.5 years later ASO, respectively, and cerebellar function
impairment (related to ataxia and coordination) was significantly
associated with a later onset in relapse-onset patients (2.91 years
later ASO). A previous study (24) found no association between
psychiatric (p= 0.31) or cognitive (p= 0.93) symptoms andASO,
but a significant relationship between sphincteric symptoms and
ASO (p = 0.012). Marked differences in the ASO between that
study and presented study (∼30 years vs. 37 years) may account
for the divergent findings.
The finding that tobacco smoking delayed the average ASO
by 4 years is counterintuitive given that it is a risk factor for
MS (5). Two other studies have shown a similar directions of
effect, with magnitudes of 2.60 years (n = 7,883) (25) and 0.82
years (n= 540) (13). A null association between tobacco smoking
and ASO in healthy controls supported that this association
was not due to an age or cohort effect. However, we note
that our controls did not show the expected decline in ever
smoker status by birth cohort 2004–05 as the general Australian
population (26). Some hidden confounder or responder bias,
e.g., with older controls being more health conscious and less
likely to be smokers may account for this (26). However, the
control sample was still a preferable comparison source than
the general Australian population, since controls resided in the
same regional locations as the cases and were age/sex-matched.
The participation rate for controls was lower than cases (20)
but this potential volunteer bias would be unlikely to lead to
altered patterns of smoking by age among the controls only. A
good explanation for the opposite relationship for tobacco use
in MS onset (27) versus ASO (13, 25) is challenging. It could
relate to the anti-inflammatory effects of nicotine upon T-cells,
B-cells, and even dendritic cells (28). Tobacco smoking may have
a greater impact on neurodegeneration rather than inflammation
and immune dysfunction (29) and older onset cases may have a
greater neurodegenerative component (30).
Marijuana use was associated with a 6.0-years earlier ASO,
despite the Ausimmune Study (5) showing no association
between marijuana use and MS risk [never vs. ever, adjusted OR
0.91 (0.84–1.54)]. Other research has demonstrated a detrimental
effect of marijuana on the CNS. Two studies (31, 32) have
showed that marijuana use was associated with poorer cognitive
performance in MS patients. Thus, there is some evidence
supporting potential deleterious impacts of marijuana use in MS,
though the means by which this occurs, requires further study.
Consistent with previous research (12, 13, 17, 33), we found
no association between sex, history of infectious mononucleosis,
HLA-A2 or HLA-DR15 genotype and ASO. Latitude of study
site, deseasonalised 25(OH)D levels and UVR dose were not
associated with ASO in the present study. Using the largeMSBase
global dataset (n = 22,162), we previously showed an inverse
association between latitude and ASO (every 10◦ increase in
latitude was associated with a 0.82-year earlier onset, p = 2.20 ×
10−13) (19). However, in line with the present study, subgroup
analysis restricting to Australian participants showed a non-
significant association. Our previous study also found that UVR
exposure from age 6 to 15 years and lifetime actinic damage were
not associated with ASO (34). Another cross-sectional study (12)
(n= 1,161) found that vitamin D-associated SNPs and vitamin D
supplementation (multivitamin/vitamin D or fatty fish) were not
associated with ASO.
While we identified some factors that were associated with
ASO, we explained only 12% of the total variance, thus leaving
the majority unexplained. We demonstrated that marijuana use
was associated with an earlier MS onset and that a history
of tobacco smoking was associated with a later ASO. Further
research is required to better understand these opposite effects
and underlying pathways. These results, if corroborated and
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supported in other studies, may aid in the understanding of MS
and potentially contribute to delaying MS onset.
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